EASL Spotlight: Liver Docs Gear Up For Wave Of New Hep C Drugs, Expect Change Soon
Publication of four Phase III studies for Gilead’s sofosbuvir in the New England Journal of Medicine reassures analysts on the safety front. But while Gilead is in the lead, its sofosbuvir-centered regimens will also face competition from several other promising new Hep C regimens in development.
You may also be interested in...
For Vertex, the key question is how much is physician and patient concern about the adverse events is already reflected in the softening sales of the hepatitis C drug; for FDA, the question is how effective will label-based risk management be.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.